User profiles for Christopher O’Callaghan

Christopher O'Callaghan

- Verified email at ucl.ac.uk - Cited by 17178

Christopher J O'Callaghan

- Verified email at ctg.queensu.ca - Cited by 12397

[HTML][HTML] Global prevalence of chronic kidney disease–a systematic review and meta-analysis

NR Hill, ST Fatoba, JL Oke, JA Hirst, CA O'Callaghan… - PloS one, 2016 - journals.plos.org
Chronic kidney disease (CKD) is a global health burden with a high economic cost to health
systems and is an independent risk factor for cardiovascular disease (CVD). All stages of …

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

VM Braud, DSJ Allan, CA O'Callaghan, K Söderström… - Nature, 1998 - nature.com
The protein HLA-E is a non-classical major histocompatibility complex (MHC) molecule of
limited sequence variability. Its expression on the cell surface is regulated by the binding of …

[HTML][HTML] FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer

…, B Juzyna, S Gourgou, CJ O'Callaghan… - … England Journal of …, 2018 - Mass Medical Soc
Background Among patients with metastatic pancreatic cancer, combination chemotherapy
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall …

[HTML][HTML] Short-course radiation plus temozolomide in elderly patients with glioblastoma

JR Perry, N Laperriere, CJ O'Callaghan… - … England Journal of …, 2017 - Mass Medical Soc
Background Glioblastoma is associated with a poor prognosis in the elderly. Survival has
been shown to increase among patients 70 years of age or younger when temozolomide …

Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

…, H Piessevaux, E Van Cutsem, CJ O'Callaghan… - Jama, 2010 - jamanetwork.com
Context Patients with metastatic colorectal cancer who have KRAS codon 12– or KRAS codon
13–mutated tumors are presently excluded from treatment with the anti–epidermal growth …

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized …

…, R Labianca, JF Seitz, CJ O'Callaghan… - Journal of Clinical …, 2005 - ascopubs.org
Purpose A traditional end point for colon adjuvant clinical trials is overall survival (OS), with
5 years demonstrating adequate follow-up. A shorter-term end point providing convincing …

Production of soluble αβ T-cell receptor heterodimers suitable for biophysical analysis of ligand binding

BE Willcox, GF Gao, JR Wyer, CA O'callaghan… - Protein …, 1999 - cambridge.org
A method to produce αβ T-cell receptors (TCRs) in a soluble form suitable for biophysical
analysis was devised involving in vitro refolding of a TCR fusion protein. Polypeptides …

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes

…, PJ Easterbrook, CA O'Callaghan… - Proceedings of the …, 2000 - National Acad Sciences
Highly active antiretroviral therapy (HAART) has been advocated for the management of
primary HIV-1 infection without clear understanding of its immunological effects. Here, we …

Family satisfaction with care in the intensive care unit: results of a multiple center study

…, S Peters, JE Tranmer, CJ O'Callaghan - Critical care …, 2002 - journals.lww.com
Family satisfaction with care in the intensive care unit: Re... : Critical Care Medicine Family
satisfaction with care in the intensive care unit: Results of a multiple center study* : Critical Care …

[HTML][HTML] Intermittent androgen suppression for rising PSA level after radiotherapy

JM Crook, CJ O'Callaghan, G Duncan… - … England Journal of …, 2012 - Mass Medical Soc
Background Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation
after radiotherapy may improve quality of life and delay hormone resistance. We assessed …